Financings in Brief: Metasyn
This article was originally published in The Gray Sheet
Executive Summary
Metasyn: Contrast imaging agent manufacturer completes $5.1 mil. financing, from which proceeds will support "ongoing development of our lead vascular agent, MS-325, including the U.S. clinical trials expected to begin in the second half of 1996," the company says. New investors Advent International and Fidelity Ventures joined existing Metasyn investors Accel Partners and Bessemer Venture Partners in the financing. Cambridge, Massachusetts-based Metasyn's MS-325 agent is intended to be used with magnetic resonance imaging systems to produce diagnostic images of blood vessels. Imaging with MS-325 "has the potential to replace a large portion of invasive, catheter- based x-ray angiograms used today," Metasyn says...